Drug search by name

Trastuzumab-dkst Intravenous and Pulmonary toxicity

Result of checking the interaction of drug Trastuzumab-dkst Intravenous and disease Pulmonary toxicity for safety when used together.

Check result:

Trastuzumab-dkst Intravenous <> Pulmonary toxicity

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity. Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis. Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity. Patients should be monitored for pulmonary symptoms. Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.

Trastuzumab-dkst Intravenous

Generic Name: trastuzumab

Brand Name: Herceptin, Kanjinti, Ogivri

Synonyms: Trastuzumab

What is Trastuzumab-dkst Intravenous?